Summary:
-
Government Response and Funding: The US government has allocated $176 million to Moderna for developing an mRNA vaccine to counter a potential bird flu pandemic, specifically targeting the H5N1 strain that is spreading among US dairy cattle. This initiative, funded through the Biomedical Advanced Research and Development Authority (BARDA), is part of a broader effort to enhance pandemic preparedness under the new Rapid Response Partnership Vehicle (RRPV) Consortium.
-
Vaccine Development and Trials: Moderna started a Phase 1/2 trial last year for vaccines targeting H5 and H7 bird flu strains. The results of this trial, expected this year, will guide the Phase 3 trial set for 2025. The current funding will support the development of a “pre-pandemic vaccine” against H5 influenza, with provisions for additional vaccines if new public health threats arise.
-
Rising Concerns and Preparedness Measures: The deal comes amid an ongoing H5N1 outbreak in dairy farms across the US, raising concerns about the virus adapting to mammalian hosts and the potential for human transmission. The Department of Health and Human Services is also working to produce 4.8 million vials of H5 influenza vaccine. A recent small study in Texas indicates human cases on dairy farms might be going undetected, emphasizing the need for vigilant pandemic preparedness.
!